Association of IL-28B rs12979860 with spontaneous HBV clearance and interferon treatment response: a Meta-analysis
-
摘要: 目的 探索白细胞介素28B(interleukin- 28B,IL-28B)基因rs12979860位点与乙型肝炎病毒(hepatitis B virus,HBV)感染后自发清除及干扰素治疗应答的关系。方法 检索2010年1月1日~2015年8月31日PubMed、Embase、中文科技期刊全文数据库、万方数据库、中国生物医学文献数据库、中国期刊全文数据库公开发表文献,对符合纳入和排除标准文献提取数据后采用Stata 12.0 软件进行Meta分析。结果 共纳入12篇文献,根据研究目的分为两组:A组为HBV自发清除组和持续感染组,共5篇文献;B组:干扰素治疗应答组和非应答组,共9篇文献。Meta分析结果:rs12979860位点与HBV感染后自发清除无关联(OR=0.96,95% CI:0.76~1.20,P=0.700);rs12979860位点与乙型肝炎e抗原阳性慢性HBV感染后干扰素治疗应答无关联(OR=0.93,95% CI:0.43~2.00,P=0.848),而突变基因型TC+TT 降低了乙型肝炎e抗原阴性慢性HBV感染后干扰素治疗应答(OR=0.47,95% CI:0.25~0.87,P=0.016)。结论 IL-28B基因的rs12979860位点突变基因型TC+TT降低了乙型肝炎e抗原阴性慢性HBV感染后干扰素治疗的应答。
-
关键词:
- 基因 /
- 肝炎, 乙型, 慢性 /
- Meta分析
Abstract: Objective To investigate the association of SNP-rs12979860 in Interleukin- 28B (IL-28B) gene with spontaneous Hepatitis B Virus (HBV)clearance and interferon treatment response in patients with chronic hepatitis B. Methods Data published from January 1, 2010 to August 31, 2015 were retrieved from PubMed,Embase,CNKI,Wan-fang database,VIP database and CBM disc. The meta-analysis was performed to analyze the data. Results Twelve papers were obtained and were divided into two groups according to the purpose of the study. Group A included five articles about rs12979860 and spontaneous HBV clearance, and group B included nine articles about rs12979860 and interferon treatment response. The meta-analysis showed that there was no association between rs12979860 and spontaneous HBV clearance (OR=0.96,95% CI:0.76-1.20,P=0.700) and the response after interferon treatment for HBeAg-positive patients (OR=0.93, 95% CI:0.43-2.00,P=0.848), respectively. There was positive correlation between rs12979860 and the response after interferon treatment for HBe-negative patients, which manifested that the mutant genotype TC+TT significantly reduced the response after interferon treatment for HB e-negative patients. (total OR=0.47, 95% CI:0.25-0.87,P=0.016). Conclusions The mutant genotype TC+TT located on rs12979860 from gene IL-28B reduced the response after the interferon treatment for HBe-negative patients.-
Key words:
- Genes /
- Hepatitis B, chronic /
- Meta-analysis
-
Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection [J]. Int J Med Sci, 2005, 2(1):50-57. Liaw YF, Chu CM. Hepatitis B virus infection [J]. Lancet, 2009, 373(9663): 582-592. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy [J]. Antivir Ther, 2006,11(6):669-679. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues [J]. Gastroenterology, 2009,137(5):1593-1608 . Tseng LH, Lin MT, Shau WY, et al. Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan [J]. Tissue Antigens, 2006,67(2):127-133. Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection [J]. Hum Mol Genet, 2003,12(19):2541-2546. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B [J]. Value Health, 2010,13(8):934-945. Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection [J]. Clin Liver Dis, 2005,9(4):541-565. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C [J]. Nat Genet, 2009, 41(10):1105-1109. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance [J]. Nature, 2009,461(7262):399-401. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study [J]. Gastroenterology, 2010,138(4):1338-1345. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy [J]. Nat Genet, 2009,41(10):1100-1104. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus [J]. Nature, 2009,461(7265):798-801. Martin MP, Qi Y, Goedert JJ, et al. IL-28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection [J]. J Infect Dis, 2010,202(11):1749-1753. Martin-Carbonero L, Rallon NI, Benito JM, et al. Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? [J]. AIDS Res Hum Retroviruses, 2012,28(10):1262-1264. Ren S, Lu J, Du X, et al. Genetic variation in IL-28B is associated with the development of hepatitis B-related hepatocellular carcinoma [J]. Cancer Immunol Immunother, 2012,61(9): 1433-1439. Peng LJ, Guo JS, Zhang Z, et al. IL-28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection [J]. Tissue Antigens, 2012,79(4):302-305. Li W, Jiang Y, Jin Q, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population [J]. Liver Int, 2011,31(8):1118-1126. Holmes JA, Nguyen T, Ratnam D, et al. IL-28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha [J]. J Gastroenterol Hepatol, 2013,28(5):861-866. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL-28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B [J]. Gastroenterology, 2012, 142(3):513-520. Lampertico P, Vigano M, Cheroni C, et al. IL-28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B [J]. Hepatology, 2013,57(3):890-896. de Niet A, Takkenberg RB, Benayed R, et al. Genetic variation in IL-28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovi [J]. Scand J Gastroenterol, 2012,47(4):475-481. Chen CM, Zhou FY, Zhou YP, et al. Relationship between single nucleotide polymorphisms in IL-28B gene and response to interferon treatment in chronic hepatitis B patients [J]. Nan Fang Yi Ke Da Xue Xue Bao, 2011,31(12):2012-2015. Wu H, Zhao G, Qian F, et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B [J]. Liver Int, 2015, 35(2): 473-481. Cheng L, Sun X, Tan S, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients [J]. Hepatol Res, 2014, 44(9):1000-1007. Kempuraj D, Donelan J, Frydas S, et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities[J]. Int J Immunopathol Pharmacol, 2004,17(2):103-106. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol 2003, 4(1): 63-68. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, et al. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C [J]. BMC Med, 2013,11:6. Wu LS, Wang H, Geng XP. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C indifferent racial populations: a meta-analysis [J]. Exp Ther Med, 2012,3(2):200-206. Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B[J]. Hepat Mon, 2011,11(3):163-172.
点击查看大图
计量
- 文章访问数: 245
- HTML全文浏览量: 50
- PDF下载量: 24
- 被引次数: 0